12个月口服伊曲康唑与6个月口服伊曲康唑预防慢性肺曲霉病复发的疗效:印度开放标签随机对照试验
在印度单中心开放标签随机对照试验中,164例未接受过抗真菌治疗的慢性肺曲霉病患者随机接受口服伊曲康唑400 mg/日治疗6个月或12个月。12个月组复发比例显著低于6个月组(10% vs 38%),绝对风险降低0.29(95%CI 0.16-0.40),首次复发平均时间更长(23个月 vs 18个月,p<0.0001)。作者认为伊曲康唑应至少给予12个月。
要点
- 12个月伊曲康唑组复发8例(10%),6个月组复发31例(38%),绝对风险降低0.29(95%CI 0.16-0.40)。
- 12个月组首次复发平均时间23个月,显著长于6个月组的18个月(p<0.0001)。
- 两组各死亡8例,不良反应发生率6个月组12%、12个月组22%,均无需调整治疗。
核心结论
- 12个月口服伊曲康唑治疗慢性肺曲霉病在减少2年复发方面优于6个月口服伊曲康唑。
- 作者认为伊曲康唑应至少给予12个月用于治疗慢性肺曲霉病。
研究设计与样本
- 单中心、开放标签、随机对照试验,在印度昌迪加尔一个胸科门诊进行,连续筛查未接受过抗真菌治疗的慢性肺曲霉病患者。
- 采用区组随机化,将合格患者随机分配至口服伊曲康唑起始剂量400 mg/日治疗6个月组或12个月组。
- 对参与者和研究者均未设盲。
- 排除无法提供知情同意、前6个月内使用任何抗真菌药物超过3周、有活动性结核分枝杆菌或非结核分枝杆菌肺病、以及过敏性、亚急性或侵袭性曲霉病的患者。
- 主要结局为治疗开始后2年时复发患者比例,所有结局均采用意向性治疗分析。
主要发现
- 12个月组复发比例显著低于6个月组:6个月组31例(38%)复发,12个月组8例(10%)复发,绝对风险降低0.29(95%CI 0.16-0.40)。
- 12个月组首次复发平均时间为23个月,显著长于6个月组的18个月(p<0.0001)。
- 共死亡16例,每组各8例。
- 6个月组81例中10例(12%)出现不良反应,12个月组83例中18例(22%)出现不良反应,均无需调整治疗。
- 两组最常见的不良事件均为恶心和厌食。
关键数值与推荐
- 主要结局为治疗开始后2年时复发患者比例。
- 12个月组复发8例(10%),6个月组复发31例(38%),绝对风险降低0.29(95%CI 0.16-0.40)。
- 12个月组首次复发平均时间23个月,6个月组18个月(p<0.0001)。
- 6个月组不良反应10/81例(12%),12个月组18/83例(22%),均无需调整治疗。
临床怎么用
- 作者认为,治疗慢性肺曲霉病时伊曲康唑应至少给予12个月。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic pulmonary aspergillosis has a 5-year mortality of 50-80% globally, and the optimal duration of treatment for chronic pulmonary aspergillosis remains unclear. We aimed to compare the effect of 6-months of oral itraconazole with 12-months of oral itraconazole on chronic pulmonary aspergillosis clinical outcomes. METHODS: In this single-centre, open-label, randomised controlled trial conducted in one chest clinic in Chandigarh, India, we screened consecutive patients with chronic pulmonary aspergillosis who were naive to antifungal treatment and randomised eligible patients, using block randomisation, to receive a starting dose of 400 mg/day of oral itraconazole for either 6 months or 12 months. There was no masking of participants or investigators. We excluded patients who were unable to provide informed consent; had an intake of any antifungal drugs for more than 3 weeks in the preceding 6 months; had active Mycobacterium tuberculosis or non-tuberculous mycobacterial pulmonary disease; and had allergic, subacute, or invasive forms of aspergillosis. The primary outcome was the proportion of patients having relapse 2 years after treatment initiation. We performed an intention-to-treat analysis for all outcomes. The study is registered with ClinicalTrials.gov, NCT03920527. FINDINGS: We recruited participants between July 1, 2019, and Aug 31, 2021. We screened 250 patients, of which 164 were included in the trial. 81 patients were randomised to the 6-month group and 83 patients were randomised to the 12-month group. The study population was 78 (48%) women and 86 (52%) men, and the mean age of participants was 44·3 (SD 13·3) years. The proportion of patients experiencing relapse was significantly lower in the 12-month group, 31 (38%) had a relapse in the 6-month group compared with 8 (10%) in the 12-month group, with an absolute risk reduction of 0.29 [95% CI 0·16-0·40]. The mean time to first relapse was 23 months in the 12-month group, which is significantly longer than the mean of 18 months in the 6-month group (p<0.0001). There were 16 deaths in total, eight in each group. Ten (12%) of 81 patients in the 6-months group and 18 (22%) of 83 patients in the 12-months group had adverse effects, with none requiring treatment modification. Nausea and anorexia were the most common adverse events in both groups. INTERPRETATION: Treatment of chronic pulmonary aspergillosis with 12 months of oral itraconazole was superior to 6 months of oral itraconazole in reducing relapses at 2 years. Itraconazole should be given for at least 12 months for treating chronic pulmonary aspergillosis. FUNDING: None. TRANSLATION: For the Hindi translation of the abstract see Supplementary Materials section.
引用
- Sehgal IS, Dhooria S, Muthu V, et al. Efficacy of 12-months oral itraconazole versus 6-months oral itraconazole to prevent relapses of chronic pulmonary aspergillosis: an open-label, randomised controlled trial in India. Lancet Infect Dis. 2022. PMID: 35429465. doi:10.1016/S1473-3099(22)00057-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。